What Ethical Issues Arise When Using Biological Samples Collected for Another Purpose?

What Changes When the Secondary Research Material Is Part of the Human Body?

A blood sample may have been drawn for a diagnostic test. Tissue may remain after surgery or pathology. Saliva, DNA, cells, or another biological specimen may have been collected for an earlier research project. Once the original purpose has been completed, the remaining material can sometimes be scientifically valuable for something entirely different.

Secondary use of biological samples resembles secondary data research in some respects, but specimens create additional questions. They can generate new information repeatedly, may reveal genetic characteristics, can sometimes be depleted by analysis, and may carry personal or cultural meanings that a row in a spreadsheet does not capture.

Secondary Biospecimen Research Can Be Valuable, but the Specimen's History Still Matters

A Biospecimen Can Generate New Information Long After Collection

Biological samples come from very different original contexts

A secondary researcher may encounter specimens originally collected for clinical diagnosis or treatment, public-health activities, forensic or administrative purposes, or another research study. These contexts should not be treated as ethically interchangeable.

A patient who allowed tissue to be removed for diagnosis did not necessarily make a research decision at that moment. Conversely, a participant in a biobank may have explicitly authorized a range of future studies.

The first question is therefore not simply “Is the sample available?” It is “Why does this sample exist, and what authorization and governance accompanied its collection and storage?”

Leftover clinical material does not automatically become research material

Clinical laboratories and pathology departments may retain material after the immediate diagnostic or treatment purpose has been fulfilled. Such residual specimens can be valuable for research, but their secondary use may trigger human-subjects, health-privacy, institutional, or other legal requirements.

OHRP advisory guidance illustrates the distinction. When leftover clinical biopsy specimens are supplied to a secondary investigator with identifiers that allow the investigator to readily ascertain donor identities, the research is treated as human-subjects research under the Common Rule framework and requires consent or an appropriate waiver. When specimens are coded so that the secondary investigator cannot readily ascertain identities, the Common Rule analysis can differ.

The precise result depends on the current regulatory framework and actual access arrangements, so researchers should obtain an authorized institutional determination rather than extrapolating from the mere fact that specimens are “left over.”

A biological sample is also an information source

A stored specimen may reveal far more than was known when it was collected. DNA sequencing, molecular assays, proteomics, metabolomics, infectious-disease testing, and other analyses can generate extensive information from material originally collected for a much narrower purpose.

This makes secondary biospecimen research distinctive. Researchers are not merely reanalyzing an existing set of observations. They may be generating entirely new data from the same physical material.

Genetic information can extend beyond the individual donor

Genomic information can reveal inherited characteristics and biological relationships. A finding about one donor may therefore carry implications for biological relatives who never contributed a specimen themselves.

This does not mean all biospecimen research is genetic research. It means that researchers should identify whether the proposed assays could generate genomic or other information with familial implications and address those risks appropriately.

The U.S. Common Rule reflects the significance of this possibility by requiring informed-consent information, when relevant, about whether biospecimen research will or might include whole-genome sequencing.

Identifiability remains central, but it is not the only ethical issue

Under OHRP guidance, research involving coded biospecimens may fall outside Common Rule human-subjects requirements when investigators cannot readily ascertain donor identities because access to the code key is appropriately restricted.

That regulatory result does not mean every secondary use is ethically interchangeable. OHRP advisory materials have emphasized that institutions may still have ethical obligations to honor agreements made with participants concerning the use of their specimens even when subsequent research uses non-readily-identifiable material.

This is the same underlying distinction encountered with de-identification in secondary data research: reduced identifiability can change regulation and risk without erasing the history of how the material was obtained.

The original consent may authorize future specimen research

Some research programs obtain prospective permission for storage and future secondary use. Under the U.S. Common Rule, broad consent is one possible mechanism for storage, maintenance, and secondary research use of identifiable private information or identifiable biospecimens.

Broad consent is not unlimited permission. Under the corresponding secondary-research exemption, limited IRB review includes determining whether the proposed research falls within the scope of the broad consent.

Researchers should therefore identify what future uses the donor actually authorized rather than treating the existence of stored material as evidence of unrestricted consent.

Samples may support research nobody anticipated when they were collected

Scientific methods can change much faster than biobanks empty their freezers. A specimen collected years ago may now support an assay that did not exist when the donor consented.

That possibility creates a difficult boundary question: whether stored samples can be used for research the donor never anticipated. The answer depends on consent scope, identifiability, governance, risk, applicable law, and the pathway under which the secondary research is proposed.

Some analyses consume or alter the specimen

Data can generally be copied without exhausting the original dataset. Biological material is different. An assay may consume part or all of a stored specimen, and preparation procedures can irreversibly alter it.

This creates stewardship questions. If material is scarce, should one proposed project be allowed to consume it? Does the repository have criteria for scientific merit and sample allocation? Are portions being preserved for clinically necessary testing or other authorized uses?

Good specimen governance therefore considers not only whether access is ethically permissible but also whether using a finite biological resource for the proposed study is justified.

Researchers need a plan for individual findings

Secondary analysis can produce findings that appear clinically significant for the person who contributed the sample. Researchers then face difficult questions about analytical validity, clinical confirmation, whether the donor can be reidentified, what the original consent promised, and whether return is required or appropriate.

The Common Rule's broad-consent provisions specifically require information, where applicable, about whether clinically relevant research results may be disclosed to participants. Its exemption for secondary research relying on broad consent also contains a condition concerning planned return of individual research results.

Researchers should therefore address return-of-results arrangements prospectively rather than improvising after an unexpected finding appears.

Commercial use can affect participant expectations

Biological materials can contribute to commercial products, diagnostic technologies, cell lines, therapeutics, or other intellectual property. Whether commercial use is permissible depends on the applicable consent, law, agreements, and institutional framework.

Under the Common Rule, informed consent must include, for research involving biospecimens, a statement regarding whether specimens may be used for commercial profit and whether the subject will or will not share in that commercial profit when applicable.

This disclosure does not settle broader debates about benefit sharing or ownership. It does, however, demonstrate that future commercial use can be material to a participant's decision.

Cultural and community considerations may matter

Some individuals and communities attach particular cultural, spiritual, familial, or collective significance to blood, tissue, DNA, or other human biological material. Ethical stewardship should not assume that every donor understands a specimen solely as laboratory material once it leaves the body.

The relevance of community consultation, collective interests, culturally appropriate governance, or restrictions on particular research uses depends on the population and context. Researchers should not invent cultural concerns on behalf of a group, but neither should they dismiss documented concerns merely because individual-level regulatory requirements have been satisfied.

Physical custody is not the same as ownership or unrestricted control

A laboratory may possess a specimen, a repository may store it, and an institution may control access, but those facts do not by themselves answer every question about ownership, donor interests, intellectual property, or rights in information derived from the material.

The question of who owns stored biological samples and the information derived from them varies across legal systems and institutional arrangements and should not be reduced to whoever currently holds the freezer key.

When Leftover Clinical Tissue Becomes a Research Resource

Common Misunderstandings About Secondary Biospecimen Research

Evaluate Both the Physical Specimen and the Information You Plan to Generate

Before using stored biological material, map its history from collection to storage. Then examine what your proposed assay will do to the physical specimen and what information it may create.

Before Using Biological Samples Collected for Another Purpose

Frequently Asked Questions About Secondary Use of Biological Samples

A Stored Specimen Is Both Biological Material and a Continuing Source of Information

How to Cite This Guide

This guide is intended to be read, shared, and used in research, teaching, and academic work. If you draw on its ideas, explanations, or other content, please acknowledge the source by citing the guide. Doing so gives appropriate credit and helps your readers locate the original resource.